

comprising the oral administration of the composition of claim 40 or claim 43.

45. The composition of claim 1, wherein said syndrome is selected from the group consisting of carcinoid-induced flush, niacin-induced flush, mesenteric fraction syndrome-induced flush, and serotonin syndrome-induced flush.

Remarks

It is the applicant's intent to limit the prosecution of this continuation-in-part/divisional patent application to the treatment of superficial vasodilator flush syndrome. All elements of these claims are supported in the specification.

To accentuate this limitation, the title of this application is also being amended, as recited above.

03/30/2004

Respectfully submitted,



Dr. Melvin Blecher
Attorney-at-Law
Registration No. 33,649

**Law Offices of Dr. Melvin Blecher
4329 Van Ness St., NW
Washington, DC 20016-5625
Tel: 202 363 3338
FAX: 202 362 8404
e-mail: MBiplaw@comcast.net**